“Second half was going be better than the first half. And 26 will be better than 25.”

In context

“d that's an area of particular strength for us that we built the scale, that we built the technology and the cost positions there. So, feel good about I good about Libre. I feel good about our U. S. Position. And the momentum that we're going have US and internationally. Robbie Marcus: I appreciate that. And then you talked about new product launches, Volt was one that you highlighted. We're expecting that I believe, around midyear. Next year in The U. S. Just maybe speak to Volt, the early feedback in Europe that you've received and how people should think about the ramp in cadence of Voalte and overall EP as we move into next year? Thanks a lot. Robert Ford: Sure. Well, we're seeing acceleration on our growth rate in EP, obviously, the second half. We knew that was going to be the case. Second half was going be better than the first half. And 26 will be better than 25. I think that you've seen here double digit growth across the board, more specifically also in our ablation catheter portfolio. So yeah, I feel good about what we've done here, Ravi. I mean, this idea that we've been playing defense over the last couple of couple of years, it's actually been a quiet offensive strategy where we've used the adoption of PSA on other competitive systems to increase our capital footprint. Now we'll be in a position to bring in the catheter, the PFA catheter It's doing very well. I just got some feedback. Yesterday and, been following, the rollout You know, it's going very well. I'd say efficacy and efficiency, those seem to be table stakes right now. PFA has proven to work and get the job done more quickly. So I think what I'm seeing now is longer term durabili”